CEO Usman Azam was paid $1,185,639 in fiscal year 2025 (SEC filing 0001193125-26-108301 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$1,426,183 Daniel Passeri total, FY2025 Former Chief Executive Officer — highest-paid officer; CEO Usman Azam: $1,185,639 | — CEO (Usman Azam) pay percentile vs peers | — CEO-to-median pay ratio | 83.35% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
CUE's next annual pay disclosure, estimated March 16, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Daniel Passeri | $240,504 | $0 | $0 | $336,555 | $0 | $0 | $849,124 | $1,426,183 |
| Former Chief Executive Officer | ||||||||
| Matteo Levisetti | 470,753 | 0 | 0 | 186,975 | 0 | 0 | 561,636 | 1,219,364 |
| Former Chief Medical Officer | ||||||||
| Usman Azam | 143,077 | 0 | 0 | 1,042,313 | 0 | 0 | 249 | 1,185,639 |
| President and Chief Executive Officer | ||||||||
| Lucinda Warren | 469,952 | 0 | 0 | 330,275 | 0 | 0 | 996 | 801,223 |
| Chief Financial and Business Officer | ||||||||
| Colin Sandercock | 448,646 | 0 | 0 | 149,580 | 0 | 0 | 996 | 599,222 |
| SVP, General Counsel and Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Daniel Passeri | $1,426,183 | $1,393,921 | — | ↑ +32,262 |
| Matteo Levisetti | 1,219,364 | 1,191,276 | — | ↑ +28,088 |
| Usman Azam | 1,185,639 | — | — | — |
| Lucinda Warren | 801,223 | — | — | — |
| Colin Sandercock | 599,222 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Cue Biopharma's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper CUE reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses CUE in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CUE in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Colin Sandercock | Option | 2,084 | 5.01 | — |
| Daniel Passeri | Option | 337,500 | 0.98 | — |
| Daniel Passeri | Option | 12,500 | 5.01 | — |
| Usman Azam | Option | 1,875,000 | 0.72 | — |
| Colin Sandercock | Option | 109,375 | 1.94 | — |
| Colin Sandercock | Option | 37,500 | 3.21 | — |
| Daniel Passeri | Option | 81,000 | 3.21 | — |
| Colin Sandercock | Option | 37,500 | 1.65 | — |
| Daniel Passeri | Option | 200,000 | 1.94 | — |
| Lucinda Warren | Option | 175,000 | 0.66 | — |
| Colin Sandercock | Option | 7,500 | 6.91 | — |
| Lucinda Warren | Option | 218,750 | 0.98 | — |
| Lucinda Warren | Option | 125,000 | 0.72 | — |
| Colin Sandercock | Option | 175,000 | 0.98 | — |
Cue Biopharma aims to offer competitive compensation to attract, retain, and motivate highly skilled management, emphasizing long-term performance-based equity compensation over base salaries and annual bonuses to align management interests with stockholders and conserve cash.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Radford, an AON Hewitt company |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-06-04 | 13,186,558 | 2,634,667 | 138,967 | 83.35% | Passed |
| 2023 | 2023-06-07 | 11,079,655 | 2,042,073 | 897,148 | 84.44% | Passed |
| 2022 | 2022-06-09 | — | — | — | — | — |
| 2021 | 2021-06-09 | — | — | — | — | — |
| 2020 | 2020-07-09 | — | — | — | — | — |
| 2019 | 2019-08-06 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2025 | 2025-06-04 | 83.35%a |
| 2023 | 2023-06-07 | 84.44%b |
| 2022 | 2022-06-09 | —c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Peter A. KienerIndependent · Compensation (Chair) · Corporate Governance and Nominating · Science and Technology Strategy (Chair) | $64,000 | — | $19,381 | — | $110,000 | $193,381 |
| Pasha SarrafIndependent · Board Chair · Corporate Governance and Nominating · Science and Technology Strategy | 50,392 | — | 37,688 | — | 0 | 88,080 |
| Patrick VerheyenIndependent · Audit · Compensation | 57,500 | — | 19,381 | — | 0 | 76,881 |
| Frank MorichIndependent · Audit · Corporate Governance and Nominating (Chair) · Science and Technology Strategy | 57,138 | — | 19,381 | — | 0 | 76,519 |
| Pamela GarzoneIndependent · Compensation · Science and Technology Strategy | 50,000 | — | 19,381 | — | 0 | 69,381 |
| Jill BroadfootIndependent · Audit (Chair) · Corporate Governance and Nominating · Newly elected | 31,500 | — | 22,765 | — | 0 | 54,265 |
| Frederick DriscollIndependent · Not standing for re-election · Departed during FY | 22,800 | — | 19,381 | — | 0 | 42,181 |
| Usman AzamEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $35,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $333,330 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $110,000 |
| Total cost of the board | $443,330 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Cue Biopharma | 2025 | Usman Azam | $143,077 | $0 | $1,042,313 | $0 | $1,185,639 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Daniel Passeri | DEF 14A | 2026-03-16 | 0001193125-26-108301 | Section “Executive Compensation”. As printed: 1,426,183. Filing ↗machine: r4 · c12 · span 467202–467211 |
| 2 | Section 01, Matteo Levisetti | DEF 14A | 2026-03-16 | 0001193125-26-108301 | Section “Executive Compensation”. As printed: 1,219,364. Filing ↗machine: r8 · c12 · span 484600–484609 |
| 3 | Section 01, Usman Azam | DEF 14A | 2026-03-16 | 0001193125-26-108301 | Section “Executive Compensation”. As printed: 1,185,639. Filing ↗machine: r2 · c12 · span 458480–458489 |
| 4 | Section 01, Lucinda Warren | DEF 14A | 2026-03-16 | 0001193125-26-108301 | Section “Executive Compensation”. As printed: 801,223. Filing ↗machine: r6 · c12 · span 475882–475889 |
| 5 | Section 01, Colin Sandercock | DEF 14A | 2026-03-16 | 0001193125-26-108301 | Section “Executive Compensation”. As printed: 599,222. Filing ↗machine: r10 · c12 · span 493280–493287 |
| 6 | Section 08, Peter A. Kiener | DEF 14A | — | — | Section “Director Compensation”. As printed: 193,381. |
| 7 | Section 08, Pasha Sarraf | DEF 14A | — | — | Section “Director Compensation”. As printed: 88,080. |
| 8 | Section 08, Patrick Verheyen | DEF 14A | — | — | Section “Director Compensation”. As printed: 76,881. |
| 9 | Section 08, Frank Morich | DEF 14A | — | — | Section “Director Compensation”. As printed: 76,519. |
| 10 | Section 08, Pamela Garzone | DEF 14A | — | — | Section “Director Compensation”. As printed: 69,381. |
| 11 | Section 08, Jill Broadfoot | DEF 14A | — | — | Section “Director Compensation”. As printed: 54,265. |
| 12 | Section 08, Frederick Driscoll | DEF 14A | 2026-03-16 | 0001193125-26-108301 | Section “Director Compensation”. As printed: 42,181. Filing ↗machine: span 392937–393146 |
| 13 | Section 08, Usman Azam | DEF 14A | — | — | Section “Director Compensation”. As printed: 0. |
| 14 | Section 06, 2025 vote | Form 8-K | 2025-06-10 | 0000950170-25-084279 | Item 5.07 · say-on-pay result. As reported: 83.35% (votes for as printed: 13,186,558). Filing ↗ |
| 15 | Section 06, 2023 vote | Form 8-K | 2023-06-09 | 0001193125-23-164491 | Item 5.07 · say-on-pay result. As reported: 84.44% (votes for as printed: 11,079,655). Filing ↗ |
| 16 | Section 06, 2022 vote | Form 8-K | 2022-06-10 | 0001193125-22-171921 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 17 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 18 | Section 09b board cost (computed) | Computed | — | — | Cash 333,330 + equity 0 + all other 110,000 = 443,330, summed across the director compensation table rows.machine: formula: Σ = 443,330 |
| 19 | Cue Biopharma (subject), Section 10b CEO total | DEF 14A | 2026-03-16 | 0001193125-26-108301 | CEO total compensation as printed in Cue Biopharma's own proxy. As printed: 1,185,639. Filing ↗machine: r2 · c12 · span 458480–458489 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.